Just a few weeks after Eli Lilly claimed a key FDA approval for its CDK4/6 inhibitor Verzenio in early-stage breast cancer, Novartis has responded with phase 3 data for Ki
Novartis has confirmed that it is no longer going ahead with a large-scale clinical trial of its cholesterol-lowering therapy Leqvio in the UK, but said other elements of
Gene-editing specialist Sangamo Therapeutics has lost not one but two sizeable partnerships with larger biopharma companies, with Novartis and Biogen both walking away fro
New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, inc
Sandoz has started building for the future after it completes a planned spin-out from parent Novartis, with a major investment in a production plant in Slovenia for its bi
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t
